AbbVie treats first subject in Phase III multiple myeloma drug trial

AbbVie has treated the first subject in the Phase III CERVINO clinical trial of its investigational product ABBV-383 to treat relapsed/refractory multiple myeloma (r/r MM).

ABBV-383 is a bispecific antibody T-cell engager that binds to both BCMA and CD3, designed to target and engage T-cells to fight cancer cells.